Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial
NCT07349771 · Mayo Clinic · PHASE2 · withdrawn · last registry update 2026-09-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor declined to fund study due to inability to agree on IP.” | – | Registry record, Mayo Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Also stopped (terminated): Gossamer Bio USA, Inc., GB002 (seralutinib) (NCT04816604)
- 2026-10-20Phase 3 first posted: Sun Yat-sen University, Benmelstobart + Anlotinib (NCT07881900)
- 2026-10-05Also stopped (suspended): M.D. Anderson Cancer Center, Cyclophosphamide + Axatilimab (SNDX-6352) (NCT06959537)
- 2026-10-05Results posted on the registry: Incyte Biosciences Japan GK, INCA034176 (NCT06263478)
- 2026-08-31Results posted on the registry: University of Texas Southwestern Medical Center, a drug against CSF1R (NCT02956798)
- 2026-08-25Also stopped (terminated): Association of Urologic Oncology (AUO), Sunitinib + Placebo (NCT01216371)
- 2026-07-09Results posted on the registry: Eli Lilly and Company, Pegilodecakin + Paclitaxel or Docetaxel and Carboplatin or Cisplatin (NCT02009449)
- 2026-07-09Also stopped (terminated): Washington University School of Medicine, Paclitaxel + Carboplatin (NCT04331067)
- 2026-04-14Also stopped (terminated): Institut Claudius Regaud, Pazopanib (NCT01642017)
- 2026-04-08Results posted on the registry: National Cancer Institute (NCI), Olaparib + Pazopanib (NCT05432791)
- 2026-03-19Also stopped (suspended): GB002, Inc., Placebo + Seralutinib (NCT07181382)
- 2026-03-18Phase 3 first posted: PETHEMA Foundation, Azacitidine + Venetoclax (NCT07478991)
- 2026-02-23Phase 3 first posted: European Organisation for Research and Treatment of Cancer - EORTC, Gilteritinib + Venetoclax (NCT07425808)
- 2025-10-21Phase 3 first posted: GlaxoSmithKline, IDRX-42 + Sunitinib (NCT07218926)
- 2025-10-16Results posted on the registry: NYU Langone Health, Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks + Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks (NCT04050462)
- 2025-10-16Also stopped (terminated): NYU Langone Health, Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks + Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks (NCT04050462)
- 2025-09-18Phase 3 first posted: GB002, Inc., Placebo + Seralutinib (NCT07181382)
- 2025-09-10Phase 3 first posted: Peking University Cancer Hospital & Institute, Vorolanib Tablets+Everolimus + Sunitinib (NCT07165418)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision